Mirtazapin Orion (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine and serotonin. It also antagonizes postsynaptic 5‑HT2, 5‑HT3 and histamine H1 receptors, producing antidepressant effects while contributing to sedation and appetite stimulation.

The appropriate dose of Mirtazapin Orion is determined by the prescribing clinician based on the patient’s clinical condition, response to therapy, and tolerability. Dosage adjustments are individualized and should follow the prescriber’s instructions.

Mirtazapin Orion falls under an unknown pregnancy category, and safety data are limited. It should only be used during pregnancy or lactation if the potential benefit justifies the potential risk, and the decision must be made by a qualified healthcare professional.

To order Mirtazapin Orion, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike selective serotonin reuptake inhibitors (SSRIs), mirtazapine acts as a NaSSA, influencing both norepinephrine and serotonin release while also blocking histamine receptors. This results in a different side‑effect profile, often causing sedation and weight gain, which can be advantageous for patients with insomnia or poor appetite.

Mirtazapin Orion should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and ensure they are out of reach of children.

Mirtazapin Orion is taken orally, usually as a tablet. It should be swallowed whole with water, and the timing (e.g., with or without food) follows the prescriber’s guidance. Patients should not crush or chew the tablet unless specifically instructed.

Serious risks include the potential for agranulocytosis or severe neutropenia, rare severe skin reactions such as Stevens‑Johnson syndrome, and the emergence or worsening of suicidal thoughts, particularly during the initial weeks of therapy. Prompt medical attention is required if any of these occur.

Mirtazapin Orion should be avoided in patients with known hypersensitivity to mirtazapine or any of its excipients, those currently taking monoamine oxidase inhibitors, and individuals with severe hepatic impairment unless a specialist advises otherwise. Pregnant or breastfeeding women should use it only if clearly indicated by a healthcare professional.